A five-year risk prediction model of cardiovascular disease in individuals with bipolar disorder: a nationwide register study from Sweden.

Journal: Molecular psychiatry
Published Date:

Abstract

Cardiovascular disease (CVD) risk prediction models for the general population may not provide accurate predictions in individuals with bipolar disorder (BD) who have elevated risks of cardiometabolic conditions and premature mortality. Therefore, we aimed to: 1) develop a five-year CVD risk prediction model in this population by using nationwide register data from Sweden, 2) investigate whether the performance improved when we considered additional risk factors, including psychiatric comorbidity, psychotropic medication, and socio-demographic variables, compared to using established CVD risk factors only, and 3) whether machine learning approach provided improvements compared to standard logistic regression models. We followed 33,933 persons with BD aged 30-82 years old, without previous CVD, from the date of BD diagnosis registered between 2007-2014, for up to five years. The logistic regression model containing only established risk factors yielded an area under the receiver operating characteristic curve (AUC) of 0.76 (95% confidence interval 0.74-0.78) in the test dataset, while the logistic regression model and the best performing machine learning model including additional predictors yielded similar results (AUC was 0.77 (0.75, 0.79) in both models). The performance of logistic regression models slightly improved with additional predictors when continuous risk scores were used. In conclusion, standard logistic regression and established CVD risk factors may be sufficient to predict CVD in individuals with BD when using population register-based data from Sweden. External validation across diverse healthcare settings and rigorous assessment of clinical impact will be crucial next steps before implementing these models in clinical practice.

Authors

  • Maja Dobrosavljevic
    School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. [email protected].
  • Mikael Landén
    Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
  • Isabell Brikell
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Zheng Chang
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, United States of America.
  • Ralf Kuja-Halkola
    Department of Medical Epidemiology and Biostatics, Karolinska Institutet, Stockholm, Sweden.
  • Paul Lichtenstein
    Department of Medical Epidemiology and Biostatics, Karolinska Institutet, Stockholm, Sweden.
  • Pontus Andell
    Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Ole A Andreassen
    NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway. Electronic address: [email protected].
  • Michael Bauer
    Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus Medical Faculty, Technische Universität Dresden, Dresden, Germany.
  • Rosa Corcoy
    Institut d'Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain.
  • Giovanni de Girolamo
    IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Andreas Reif
  • Henrik Larsson
    Department of Medical Epidemiology and Biostatics, Karolinska Institutet, Stockholm, Sweden.
  • Miguel Garcia-Argibay
    School of Medical Sciences, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. [email protected].

Keywords

No keywords available for this article.